Menopause Hormone therapy vs. Breast Cancer: "Is What I'm Thinking True?"

“Is what I’m thinking actually true?”

Have you, or someone you love, ruled out hormone therapy because you are afraid of breast cancer?

You deserve to understand what the information means FOR YOU before that fear makes your decision.

Interpreting RISK is not something our culture understands very well. There’s a chance you have never been taught how to interpret it—and a chance that an adequate amount of time has not yet been allocated in your health appointment to review your OWN PERSONAL benefits-versus-risks equation.

When you hear that a study found more breast cancer diagnoses among women taking a particular hormone therapy protocol, you are hearing a finding about a group. How often new cases occur in a population over time is called incidence. Your personal risk assessment asks how the evidence applies to you, given your current age, health history and other circumstances.

The two are connected. They are not interchangeable. And neither a population statistic nor the fact that someone took hormone therapy can, on its own, explain what caused her individual cancer.

You DESERVE a personalized conversation in order to make the best health decisions for you.

You also deserve a reminder that there are risks to everything, including risks to not pursuing certain options.

It does not take long for a menopause conversation to arrive at hormone therapy, or for that conversation to veer towards breast cancer concrns. So let’s go there. Breast cancer is a real, powerful and overwhelming health topic. No one wants to make a decision they believe will put them in danger.

No one I know wants breast cancer. Most women I speak with also do not want to live with vasomotor symptoms—hot flashes and night sweats—vulva & vaginal dryness, or osteoporosis. You deserve an investigative conversation about all of it.

What does “1 in 8” actually mean?

You have probably heard that one in eight women will develop breast cancer.

The words that are almost always omitted are: “over her lifetime.” 1-in-8 applies if we live to 85. If you are not yet 85, different odds apply to you.

Dense Breasts Canada on Instagram

As Dense Breasts Canada explains in the post shared here, that statistic describes estimated risk accumulated across a lifetime extending to approximately age 85 or 90. It does not mean every woman has a one-in-eight chance this year, at her current age or over the next ten years.

“1 in 8” is an estimated lifetime probability, not an annual incidence rate.

Your current age and the period being discussed matter. Being 61 and being 69 are not interchangeable simply because both ages fall within your 60s. A personal assessment uses your actual age and circumstances; it does not assign you a probability solely because you belong to an age band.

It is easy to build a headline around “1 in 8.” The number commands attention and may help fundraise for important breast cancer research and care. Explaining what it means takes more time and a deeper understanding.

If we use a statistic to capture your attention, we owe you the explanation that makes it useful to you!

What belongs in YOUR breast cancer assessment?

Being female and increasing age are major breast cancer risk factors.

“Having breasts” is familiar shorthand, but breast size is not the issue, and men can develop breast cancer too.

Your assessment also considers family history, including a first-degree relative—a mother, sister or daughter—with breast cancer, her age at diagnosis, other affected relatives and inherited genetic variants. Family history on your father’s side matters too.

Alcohol consumption, body weight after menopause and physical activity belong in the conversation.

So does breast density: dense tissue is associated with higher breast cancer risk and can make cancer harder to detect on a mammogram. Those are separate considerations about developing cancer and detecting it.

These known risk factors help inform a clearer picture; they cannot simply be added together to calculate your probability.

Having a risk factor is not a diagnosis, and having few known risk factors is not a guarantee. The goal is understanding, not blame.

Hormone therapy does not = breast cancer

Knowing that a woman took hormone therapy and later developed breast cancer does not, by itself, establish what caused her individual cancer. We also cannot put every hormone therapy protocol into the same bucket.

The Women’s Health Initiative (WHI) combined-therapy trial studied oral conjugated equine estrogens plus medroxyprogesterone acetate, a synthetic progestin. It did not study transdermal estradiol plus oral micronized progesterone.

The separate WHI estrogen-alone trial, among women who had undergone hysterectomy, produced different findings, including lower breast cancer incidence over long-term follow-up.

The 2022 Hormone Therapy Position Statement describes estimates of less than one additional breast cancer case per 1,000 women per year, or approximately three additional cases per 1,000 women over five years with conjugated equine estrogens plus medroxyprogesterone acetate. menopause.org

“Additional” matters. These figures describe a difference compared with a comparison group—not the total number of women diagnosed with breast cancer.

Three additional cases per 1,000 women over five years is an absolute difference of 0.3 percentage points over those five years. It is not three additional cases every year, and it does not mean your total personal breast cancer probability is 0.3%. The annual and five-year estimates are not a progression from one case to three cases simply because a woman becomes five years older.

Is that what you understood when you heard “increased risk”?

A randomized trial can provide evidence that a specific treatment changes how often an outcome occurs. But its population findings do not identify the cause of an individual woman’s cancer. Nor can a finding about one protocol be applied indiscriminately to every protocol. A different formulation does not automatically mean no risk; you deserve the evidence relevant to the option being considered for you.

Words matter: hormones and hormone therapy

Your naturally produced hormones, changes in their production and prescribed menopause hormone therapy are related subjects. They are not interchangeable.

Systemic hormone therapy and local/vaginal estrogen are not interchangeable either. If your goal is to address vasomotor symptoms (hot flashes and night sweats) or prevent bone loss, the conversation the conversation can't stop there; it needs to also include prevention and/or treatment of vulva & vaginal dryness or urinary symptoms.

Advocates including Let’s Talk Menopause challenged the broad US boxed warning on local vaginal estrogen. The FDA initiated warning changes in November 2025 and approved revised labels for an initial six hormone therapy products in February 2026, removing cardiovascular disease, breast cancer and probable dementia statements from their boxed warnings.

The endometrial cancer warning for systemic estrogen-alone products remained; that is because estrogen cannot go unopposed in someone with a uterus.

These changes do not automatically change Canadian labels (yet.) or make every treatment appropriate for every woman. They do give us another reason to revisit explanations that may have shaped our decisions for years.

A warning can remain in your mind long after its wording changes. You deserve an updated conversation on what your own individual benefits vs. risk profile actually is.

There are risks to leaving concerns unaddressed

The last thing women need is to avoid investigating their options because of fear—and then be left without a plan for their symptoms or future health.

Your breast health deserves attention. So do your heart, bones, sleep and vulva & vaginal health.

For your heart, investigate blood pressure, cholesterol, blood sugar, family history and other relevant factors, whether or not you choose hormone therapy. Hormone therapy will not be prescribed solely to prevent heart disease; preventing heart disease is multi-factorial.

Menopause hormone therapy can prevent bone loss and fractures; it is essential to have a conversation about all the appropriate ways to prioritize your bone health, including the potential benefits for your bones.

For genitourinary health including the prevention of urinary tract infections, everyone postmenopause needs to consider vaginal hormone therapy (for life) as one prong of your vulva, vaginal and pelvic health plan.

What does this mean FOR ME?

As you prepare for your health conversations, I invite you to ask:

• What are the potential benefits of menopause hormone therapy FOR ME?

• Help me understand any personal risks FOR ME, using absolute risks in relation to the benefits I would be missing, and a clear timeframe

• Which protocol are we discussing, and how does the evidence apply to my own health history?

• What other options are available, including approved non-hormone treatments?

• What could happen if I leave this concern unaddressed?

• How and when will we review the decision together?

This is why hormone therapy is an individualized decision. You cannot determine what is appropriate for you from headlines or hearsay, or hooks on social media. Shared decision-making belongs in partnership with an informed, experienced practitioner who can investigate your circumstances and explain your options.

In his 2018 International Menopause Society presentation, Dr. Robert Reid explained how frightening first impressions and misunderstandings about risk can shape decisions. He called on clinicians to bridge the gap between medical evidence and the messages women encounter elsewhere.

You deserve that bridge. You do not have to arrive knowing whether you want hormone therapy. You can arrive knowing your goals, what is affecting your life and what you want to investigate.

You deserve to feel amazing. You deserve information that makes sense to you. And you deserve a benefits-versus-risks conversation about YOU.